Drugs / SAFIMALTIB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06788509 | Dec 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, castration-resistant prostate carcinoma, myelodysplastic syndrome | Janssen Research & Development, LLC | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT04876092 | Jul 2021 → Feb 2025 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04657224 | Feb 2021 → Jan 2025 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03900598 | Apr 2019 → May 2025 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAFIMALTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095244 ↗ |
| Known as | JNJ-67856633 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04657224 ↗ |
| Known as | JNJ-67856633-ZAF | “JNJ-67856633-ZAF (referred as JNJ-67856633) is an orally bioavailable, potent, and selective first-in-class mucosa-associated lymphoid tissue lymphoma translocation protein-1...” NCT04876092 ↗ |
| Action | Inhibit | “JNJ-67856633 is a MALT1 inhibitor” NCT03900598 ↗ |
| Modality | Small molecule | — CHEMBL5095244 ↗ |
| Route | Oral | “JNJ-67856633 capsule will be administered orally.” NCT03900598 ↗ |
| Target | MALT1 | “JNJ-67856633 is a MALT1 inhibitor” NCT03900598 ↗ |